Capstone Asset Management Co. lowered its stake in shares of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) by 0.8% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 9,562 shares of the biopharmaceutical company’s stock after selling 79 shares during the period. Capstone Asset Management Co.’s holdings in Regeneron Pharmaceuticals were worth $3,844,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of REGN. Nordea Investment Management AB raised its stake in Regeneron Pharmaceuticals by 39.9% in the second quarter. Nordea Investment Management AB now owns 33,264 shares of the biopharmaceutical company’s stock valued at $11,617,000 after buying an additional 9,480 shares in the last quarter. Harding Loevner LP acquired a new stake in Regeneron Pharmaceuticals during the second quarter valued at about $58,021,000. Eqis Capital Management Inc. raised its stake in Regeneron Pharmaceuticals by 4.5% in the second quarter. Eqis Capital Management Inc. now owns 4,555 shares of the biopharmaceutical company’s stock valued at $1,591,000 after buying an additional 197 shares in the last quarter. Boulegeris Investments Inc. raised its stake in Regeneron Pharmaceuticals by 17.0% in the second quarter. Boulegeris Investments Inc. now owns 1,585 shares of the biopharmaceutical company’s stock valued at $554,000 after buying an additional 230 shares in the last quarter. Finally, First Western Capital Management Co raised its stake in Regeneron Pharmaceuticals by 80.5% in the second quarter. First Western Capital Management Co now owns 4,810 shares of the biopharmaceutical company’s stock valued at $1,680,000 after buying an additional 2,145 shares in the last quarter. 68.26% of the stock is owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Shares of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) traded down 0.80% during mid-day trading on Tuesday, reaching $387.26. The company had a trading volume of 752,140 shares. The company has a market capitalization of $40.60 billion, a P/E ratio of 56.50 and a beta of 1.79. The firm has a 50-day moving average of $381.52 and a 200-day moving average of $389.62. Regeneron Pharmaceuticals Inc. has a 12-month low of $325.35 and a 12-month high of $563.79.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Friday, November 4th. The biopharmaceutical company reported $3.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.73 by $0.40. Regeneron Pharmaceuticals had a net margin of 16.52% and a return on equity of 21.51%. The business earned $1.22 billion during the quarter, compared to analyst estimates of $1.29 billion. During the same period in the prior year, the business posted $3.47 earnings per share. The company’s revenue was up 7.3% on a year-over-year basis. On average, equities analysts anticipate that Regeneron Pharmaceuticals Inc. will post $11.73 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Capstone Asset Management Co. Sells 79 Shares of Regeneron Pharmaceuticals Inc. (REGN)” was originally posted by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are reading this story on another site, it was stolen and republished in violation of United States & international copyright & trademark law. The correct version of this story can be read at https://www.thecerbatgem.com/2016/11/29/capstone-asset-management-co-sells-79-shares-of-regeneron-pharmaceuticals-inc-regn.html.

A number of equities analysts have recently weighed in on the company. Leerink Swann set a $511.00 target price on Regeneron Pharmaceuticals and gave the stock a “buy” rating in a research note on Saturday, August 6th. RBC Capital Markets reiterated a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Saturday, August 6th. Goldman Sachs Group Inc. reiterated a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday, August 10th. Piper Jaffray Cos. set a $447.00 target price on Regeneron Pharmaceuticals and gave the stock a “hold” rating in a research note on Sunday, October 30th. Finally, Cowen and Company set a $430.00 target price on Regeneron Pharmaceuticals and gave the stock a “hold” rating in a research note on Sunday, October 30th. One analyst has rated the stock with a sell rating, thirteen have given a hold rating and twelve have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $468.87.

In other news, Director Joseph L. Goldstein sold 2,125 shares of the stock in a transaction dated Monday, November 14th. The shares were sold at an average price of $450.00, for a total transaction of $956,250.00. Following the completion of the sale, the director now directly owns 15,125 shares in the company, valued at $6,806,250. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Arthur F. Ryan sold 2,000 shares of the stock in a transaction dated Tuesday, November 15th. The stock was sold at an average price of $429.34, for a total transaction of $858,680.00. Following the sale, the director now owns 36,500 shares of the company’s stock, valued at $15,670,910. The disclosure for this sale can be found here. Company insiders own 10.40% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.

5 Day Chart for NASDAQ:REGN

Receive News & Stock Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.